Description
Indication & Scope
- Mechanism
Inhibit BCR-ABL, c-KIT and PDGFR kinases, block oncogenic signal transduction - Drug class
First-generation oral multi-targeted tyrosine kinase inhibitor - Clinical use
Philadelphia chromosome-positive leukemia, c-KIT positive gastrointestinal stromal tumor and related myeloproliferative disorders
| Generic Name | Imatinib Mesylate Tablets |
| Brand Name | Glivec® |
| Ingredient | Imatinib Mesylate |
| Dosage Form | Film-coated Tablets |
| Package | 0.1g*60 tablets/box |
| Conditions Treated | Hematological malignancies: Ph+ chronic myeloid leukemia(CML), Ph+ acute lymphoblastic leukemia(ALL), myelodysplastic/myeloproliferative neoplasms, hypereosinophilic syndromeSolid tumors: unresectable/metastatic gastrointestinal stromal tumor(GIST), adjuvant therapy for resected GIST |
| Taboos | Hypersensitivity to imatinib or excipients, pregnancy and lactation |
| Place of origin | Wehr, Germany |
| Priscription Type | Prescription drug (Rx) |
| Storage Conditions | Store below 30°C, sealed and light-proof |
| Manufacturer | Novartis Pharma Produktions GmbH |
| Registration Authority | National Medical Products Administration (NMPA) |
| Approval number | HJ20150112 |
| Approval Date | September 27, 2023 |
| Shelf Life | 36 months |
How to use ?
Recommended Dose: Chronic-phase CML: 400mg once daily orally; accelerated/blastic phase CML: 600mg once daily; Adult Ph+ ALL: 600mg daily; Unresectable/metastatic GIST: 400–600mg daily; adjuvant GIST treatment: 400mg daily for 3 years; Dose adjustment: Reduce dosage or suspend administration for severe hematologic or non-hematologic toxicities
Time: Take with large glass of water, with meals to reduce gastrointestinal irritation; continuous administration until disease progression or intolerable toxicity
Interaction: Avoid strong CYP3A4 inhibitors/inducers; adjust dose when combined with warfarin
Side effects: Edema, nausea, diarrhea, muscle cramp, fatigue, rash, myelosuppression; severe risks: severe fluid retention, liver injury, congestive heart failure
Important Notice
This product shall only be used for post-exposure rabies prophylaxis by professional medical staff. It must be applied combined with rabies vaccine and injected via wound infiltration plus intramuscular routes as specified. Do not administer intravenously or alter the dosage at will. Hypersensitivity monitoring is required throughout the whole injection process.
Packaging & Shipping
Packaging
Original manufacturer’s packaging with secure export carton. Customized export packaging is available upon request.
Shipping Methods
Express Courier (EMS, DHL, FedEx, UPS), Air Freight, and Sea Freight. Cold-chain transportation is available for products requiring temperature-controlled logistics.
Export Support
Certificate of Analysis
GMP Certificate
Commercial Invoice
Packing List & CPP
Cold Chain Logistics
Customs Documentation
Scientific and regulatory sources
FAQ
Why should patients take imatinib with meals?
To decrease gastrointestinal adverse reactions.
What core target does imatinib act on for CML treatment?
BCR-ABL fusion tyrosine kinase.
What long-term adjuvant indication does it have?
Postoperative adjuvant therapy for resected GIST.
What is the treatment cycle characteristic of imatinib?
Continuous daily oral administration without fixed off-treatment cycle.
Glivec® | Imatinib Mesylate Tablets | CML, GIST and ALL | DengYueRX
INN: Imatinib Mesylate
Indications: CML (Chronic Myeloid Leukemia), GIST (Gastrointestinal Stromal Tumor) and ALL (Acute Lymphoblastic Leukemia)
Dosage Form: Film-coated Tablets
Strength: 0.1g/Tablet
Original price was: $905.29.$769.50Current price is: $769.50.
Low MOQ
WHO-GMP
Worldwide Delivery
Compliance and Regulatory Documents
Related Products
